Search results
Pages
-
- Toxicity, response and survival in older patients with metastatic melanoma treated with checkpoint inhibitors
-
- Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease
-
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
-
- First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients
-
- Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls
-
- Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)
-
- Association of anti-TNF with decreased survival in steroid refractory Ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry
-
- Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program